The healthy immune system protects against infection and\nmalignant transformation without causing significant damage\nto host tissues. Immune dysregulation results in diverse\npathologies including autoimmune disease, chronic\ninflammatory disorders, allergies as well as immune\ndeficiencies and cancer. Phosphoinositide 3-kinase (PI3K)\nsignalling has been shown to be a key pathway in the\nregulation of the immune response and continues to be the\nfocus of intense research. In recent years we have gained\ndetailed understanding of PI3K signalling, and saw the\ndevelopment of potent and highly selective small molecule\ninhibitors, of which several are currently in clinical trials for the\ntreatment of immune-related disorders and cancer. The role\nof PI3K signalling in the immune response has been the\nsubject of detailed reviews; here we focus on relevant recent\nprogress in pre-clinical and clinical development of PI3K\ninhibitors.
Loading....